Back to results
US 8,133,976 B2Granted
Methods of use of the TACI/TACI-L interaction
AssigneeImmunex Corporation
InventorsRaymond G. Goodwin, Wanwan S. Din
Life of this patent
Estimating the term…
Abstract
The invention discloses a novel interaction between a TNF receptor (TACI) and its interacting ligand (TACI-L). Also disclosed are methods of screening candidate molecules to determine potential antagonists and agonists of the TACI/TACI-L interaction. The use of the antagonists and agonists as therapeutics to treat autoimmune diseases, inflammation, and to inhibit graft vs. host rejections is further disclosed.
Claims1
A method of inhibiting cellular activation through the binding of TACI (SEQ ID NO:2) to TACI-L (SEQ ID NO:4), comprising
- (a) exposing a cell expressing a TACI-L polypeptide of SEQ ID NO:4 to a TACI-Fc conjugate comprising amino acids 2-166 of SEQ ID NO:2 conjugated to a human Fc domain;
- (b) allowing the TACI-Fc conjugate to bind the TACI-L polypeptide;
- and
- (c) inhibiting the binding of an endogenous TACI polypeptide comprising SEQ ID NO:2 to the TACI-L polypeptide and thereby inhibiting the activation of the cell.
1 more element
Dependencies are inferred from the claim text.